Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar;3(1-2):27-38.
doi: 10.1007/s11302-006-9034-y. Epub 2007 Jan 3.

P2 purinergic receptor modulation of cytokine production

Affiliations

P2 purinergic receptor modulation of cytokine production

Christopher A Gabel. Purinergic Signal. 2007 Mar.

Abstract

Cytokines serve important functions in controlling host immunity. Cells involved in the synthesis of these polypeptide mediators have evolved highly regulated processes to ensure that production is carefully balanced. In inflammatory and immune disorders, however, mis-regulation of the production and/or activity of cytokines is recognized as a major contributor to the disease process, and therapeutics that target individual cytokines are providing very effective treatment options in the clinic. Leukocytes are the principle producers of a number of key cytokines, and these cells also express numerous members of the purinergic P2 receptor family. Studies in several cellular systems have provided evidence that P2 receptor modulation can affect cytokine production, and mechanistic features of this regulation have emerged. This review highlights three separate examples corresponding to (1) P2Y₆ receptor mediated impact on interleukin (IL)-8 production, (2) P2Y₁₁ receptor-mediated affects on IL-12/23 output, and (3) P2X₇ receptor mediated IL-1β posttranslational processing. These examples demonstrate important roles of purinergic receptors in the modulation of cytokine production. Extension of these cellular observations to in vivo situations may lead to new therapeutic strategies for treating cytokine-mediated diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet. 2001;357:1863–1869. doi: 10.1016/S0140-6736(00)04959-X. - DOI - PubMed
    1. Casanova J-L, Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol. 2004;4:55–66. doi: 10.1038/nri1264. - DOI - PubMed
    1. Billiau A, Heremans H, Matthys P. The use of cytokine knockouts in animal models of autoimmune disease. In: Fantuzzi G, editor. Cytokine knockouts. 2. Totowa, NJ: Humana; 2003. pp. 33–55.
    1. Bathon JM, Martin RW, Fleischman RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586–1593. doi: 10.1056/NEJM200011303432201. - DOI - PubMed
    1. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594–1602. doi: 10.1056/NEJM200011303432202. - DOI - PubMed

LinkOut - more resources